comparemela.com

Latest Breaking News On - Brian orelli - Page 5 : comparemela.com

Is the FDA's Partial Hold Bad News for Gilead Investors?

If Gilead has bad news on magrolimab, it could ripple throughout the industry.

Brian-orelli
Keith-speights
Pfizer
Gilead-sciences
Boehringer-ingelheim
Drug-administration
With-gilead-science
Motley-fool
Gilead-science
Forty-seven
Trillium-therapeutics

Why Investors Should Be Watching Vertex Pharmaceuticals

The company has several big opportunities on the horizon.

United-states
America
Brian-orelli
Keith-speights
Vertex-pharmaceuticals
Motley-fool
North-america

Why This Healthcare Giant Expects Decreased Covid Profits in 2022

Abbott may soon be returning to its pre-pandemic days.

Brian-orelli
Keith-speights
Motley-fool
With-abbott
Wall-street

2 Exciting Trends That Could Shape Healthcare's Future

These underappreciated opportunities in healthcare are worth a closer look.

Brian-orelli
Keith-speights
Vertex-pharmaceuticals
Motley-fool
Beam-therapeutics

What's the Outlook for Arbutus Biopharma?

The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.

Brian-orelli
Keith-speights
Arbutus-biopharma
Motley-fool-live

vimarsana © 2020. All Rights Reserved.